Kazakhstan offers one of Central Asia's most established clinical research environments, with major hospital networks in Almaty and Astana, EAEU regulatory alignment, and patient access across several high-burden therapeutic areas.
Kazakhstan is the ninth-largest country in the world by land area; a vast steppe nation of approximately 19.6 million people spanning Central Asia, bordering Russia to the north, China to the east, and the Caspian Sea to the west. Its population is distributed across two dominant urban anchors: Almaty (~2.2 million), the former capital and undisputed commercial, medical, and clinical research centre of the country; and Astana (~1.3 million), the current capital built from the steppe in the 1990s and now home to a rapidly developing modern healthcare infrastructure. Secondary cities; Shymkent (~1.2 million), Karaganda, Aktobe, Semey; each host medical universities and regional hospital networks that extend Kazakhstan's clinical research geography well beyond its two major hubs. A founding member of the Eurasian Economic Union (EAEU) since 2015, a WTO member since the same year, and a country whose oil and mineral revenues have funded sustained healthcare modernization, Kazakhstan is Central Asia's most commercially mature and infrastructure-ready research market.
Clinical trials are regulated by the Ministry of Health of the Republic of Kazakhstan and its Committee for Medical and Pharmaceutical Control (CMPC), operating under a national pharmaceutical regulatory framework harmonized with the EAEU Common Pharmaceutical Market; a unified regulatory space covering Kazakhstan, Russia, Belarus, Armenia, and Kyrgyzstan. The EAEU GCP standard, aligned closely with ICH-GCP principles, governs clinical research conduct across member states, and data generated under this framework is recognized across the full EAEU market. Kazakhstan's pharmaceutical market has grown significantly with rising per-capita health expenditure and now represents approximately $1.5–2 billion annually; attracting growing CRO investment and accelerating both site infrastructure and investigator training programs, particularly in Almaty and Astana.
Kazakhstan's population reflects its extraordinary history as a crossroads of civilisations, Soviet-era demographic engineering, and post-independence migration patterns. Approximately 70% of the population identifies as ethnic Kazakh; a Turkic people with distinctive Central Asian genetic ancestry shaped by nomadic culture and deep steppe heritage; alongside a Russian minority (~17%, concentrated in the north), Uzbek (~3%, concentrated in the south), and smaller communities including a notable Korean diaspora (Koryo-saram, descendants of Koreans deported from the Soviet Far East by Stalin in 1937), as well as Uyghur, German, Ukrainian, and Tatar communities. This ethnic mosaic creates a population of genuine pharmacogenomic interest: the Kazakh genetic profile; reflecting nomadic Central Asian, Mongolian, and Turkic admixture with distinct ancestral lineages; is substantively different from Russian, European, and South Asian comparator populations, creating patient cohorts of value for studies targeting genetic sub-group analysis across Turkic and Central Asian ancestry groups. Literacy stands at approximately 99.8%. Russian remains the primary language of medical and scientific communication, while English proficiency is growing steadily among the younger generation of physicians trained at Nazarbayev University and international institutions.
Kazakhstan's disease burden carries several markers of both its post-Soviet inheritance and its specific Central Asian epidemiological environment. Cardiovascular disease is the leading cause of death, responsible for approximately 50–55% of national mortality, creating large treatment-naïve pools in coronary artery disease, hypertension, heart failure, and stroke against a backdrop of limited prior access to modern pharmacotherapy. Cancer is the second-leading cause of mortality, with an epidemiologically distinctive feature: Kazakhstan and the adjacent Central Asian region carry among the world's highest recorded rates of esophageal squamous cell carcinoma (ESCC); driven by dietary patterns, nitrosamine exposure, and genetic susceptibility; representing a globally rare concentration of untreated esophageal cancer patients of direct relevance to oncology sponsors. Eastern Kazakhstan; particularly the Semey (formerly Semipalatinsk) region; carries a well-documented radiation exposure legacy from Soviet-era nuclear testing at the Polygon, creating elevated rates of thyroid malignancy, haematologic cancers, and radiation-related conditions in a population that has been medically studied for decades. Metabolic disease, tuberculosis (including MDR-TB), hepatitis B and C, and respiratory disease complete a diverse therapeutic landscape.
The EAEU gateway; why Kazakhstan means more than 19.6 million people: Kazakhstan's membership in the Eurasian Economic Union transforms its research value beyond the domestic population. The EAEU pharmaceutical framework creates a single regulatory market spanning Kazakhstan, Russia, Belarus, Armenia, and Kyrgyzstan; a combined addressable population of approximately 183 million people. Clinical trial data generated under EAEU GCP standards in Kazakhstan is recognized across the full EAEU market for regulatory submissions. For sponsors targeting Russia, or building CIS-wide regulatory dossiers, Kazakhstan is the most operationally accessible and commercially predictable EAEU entry point; offering EAEU-recognized data quality in a politically stable, investor-friendly environment that has progressively improved its clinical research regulatory transparency over the past decade.
Kazakhstan's proposition is scale, framework, and access. Central Asia's largest patient market; nearly 20 million people with substantial treatment-naïve NCD burden; sits within an EAEU regulatory framework whose data is recognized across a 183-million-person pharmaceutical market, supported by modern Almaty and Astana hospital infrastructure, more than eight medical universities feeding a growing investigator pipeline, and per-patient economics that sit well below any European or East Asian comparator.
EAEU Common Pharmaceutical Market membership; regulatory data recognized across Russia, Belarus, Armenia, and Kyrgyzstan; Ministry of Health and CMPC oversight; EAEU GCP standard closely aligned with ICH-GCP; institutional ethics committee review at major research sites; progressive regulatory modernization with growing international pharmaceutical engagement since WTO accession in 2015.
Per-patient and site operational costs significantly below Western Europe, East Asia, and established CIS markets; competitive investigator fees; Almaty's direct air connectivity to major European, Russian, Chinese, and Middle Eastern hubs reduces sponsor monitoring costs; oil-funded healthcare investment keeps Almaty and Astana infrastructure competitive without sponsor capital outlay.
19.6 million people; Central Asia's largest single clinical research market; deep cardiovascular treatment-naïve pools; world-class esophageal cancer patient concentrations in the Central Asian corridor; distinctive Kazakh-Turkic genetic profiles for pharmacogenomic sub-studies; Korean diaspora adding ancestral diversity; young median population; high trial compliance from a health-literate population motivated by limited novel therapy access.
8+ medical universities producing a sustained investigator pipeline; Almaty anchor sites (KazNMU, Kazakh Oncology Institute, Syzganov Surgery Center) with decades of research experience; Astana's University Medical Center and National Scientific Medical Center representing modern investment-era infrastructure; Semey Medical University with unique radiation medicine research depth; growing IQVIA, Cromos Pharma, ICON, and Parexel presence.
Cardiovascular disease anchors Kazakhstan's trial portfolio; the country's 50–55% cardiovascular mortality rate generates patient pools in hypertension, coronary artery disease, and heart failure that are both large and predominantly treatment-naïve relative to advanced pharmacotherapy. Oncology has two faces: a general cancer burden rising with population ageing and urbanisation, and the globally distinctive esophageal squamous cell carcinoma concentration in Central Kazakhstan and southern regions; one of the world's highest ESCC incidence rates and a genuinely rare patient pool for sponsors in upper GI oncology. Infectious disease carries two notable markers; multidrug-resistant tuberculosis (MDR-TB), for which Kazakhstan has been a significant global trial site, and hepatitis B and C with elevated CIS-pattern prevalence. The Semey region adds a unique specialist dimension in radiation oncology, thyroid cancer, and haematological malignancies with documented exposure aetiology. Metabolic disease, neurology, rheumatology, and nephrology round out an increasingly broad commercially active portfolio as Almaty's investigator community grows more internationally connected.
Almaty dominates Kazakhstan's clinical research landscape; as the former capital and largest city, it houses the country's oldest medical university, its leading oncology and surgical research institutes, and the majority of CRO operational hubs. Astana is rising fast, with the University Medical Center and National Scientific Medical Center now attracting first-in-EAEU trial programs in cardiology and oncology. Semey's unique radiation medicine legacy, and the medical university hospitals in Karaganda, Shymkent, and Aktobe, together extend Kazakhstan's research geography across the vast country's major population corridors.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Asfendiyarov Kazakh National Medical University Clinical Campus | Almaty | Kazakhstan's oldest and most prestigious medical institution (founded 1930) and the backbone of the national investigator pipeline; affiliated clinical hospitals serving as the primary academic trial base in Almaty; Phase II–IV across cardiovascular, oncology, neurology, endocrinology, and infectious disease; the primary portal for international sponsors building first Kazakhstani site relationships, with the deepest GCP-trained investigator community in Central Asia. |
| 02 | Kazakh Scientific Research Institute of Oncology and Radiology | Almaty | Kazakhstan's national cancer research institute and the primary oncology trial site in the country; KazNMU affiliate; Phase I–IV across solid tumours and haematologic malignancies; the leading site for esophageal cancer trials given the Central Asian region's world-leading ESCC incidence rates; active participation in CIS oncology research networks and growing international commercial sponsor partnerships. |
| 03 | National Scientific Center of Surgery named after A.N. Syzganov | Almaty | Kazakhstan's premier surgical and cardiovascular research institute, named after the founding figure of Kazakhstani surgery; Phase II–IV in cardiovascular surgery, interventional cardiology, vascular disease, and hepatobiliary surgery; modern infrastructure and a highly experienced investigator team; one of Central Asia's most capable sites for Phase III cardiovascular outcomes and complex surgical indication trial programs. |
| 04 | Republican Diagnostic Center | Almaty | A major multispecialty diagnostic and clinical research centre in Almaty; Phase II–IV across internal medicine, cardiology, metabolic disease, and rheumatology; large patient throughput from the greater Almaty metropolitan area; established relationships with international CROs and an active commercial Phase III portfolio particularly in cardiovascular and endocrinological indications. |
| 05 | National Scientific Medical Center | Astana | Kazakhstan's flagship academic hospital in the capital, representing the country's most significant post-independence healthcare infrastructure investment; Astana Medical University affiliate; Phase I–IV across cardiology, oncology, neurology, endocrinology, and general surgery; the anchor site for first-in-EAEU trial programs in Astana and increasingly preferred by international sponsors for its modern infrastructure and capital city regulatory access. |
| 06 | University Medical Center (Nazarbayev University) | Astana | Kazakhstan's most internationally oriented hospital, operated in partnership with Nazarbayev University and designed to Western hospital management standards; Phase II–IV across oncology, cardiovascular, and metabolic disease; English-language clinical environment with a faculty recruited from international academic medical centres; the preferred site for sponsors requiring the closest alignment to Western hospital research infrastructure standards within the EAEU. |
| 07 | Semey Medical University Hospital | Semey | The clinical base of Semey Medical University, situated in the city adjacent to the former Soviet Semipalatinsk nuclear test site (the Polygon); Phase II–IV with a uniquely deep research heritage in radiation medicine, thyroid oncology, haematological malignancies, and radiation-related conditions in exposed populations; the world's most experienced academic centre for studying long-term radiation health effects in civilian populations; a specialist research asset with no parallel in the region. |
| 08 | Karaganda Medical University Hospital | Karaganda | Central Kazakhstan's academic teaching hospital and the clinical base of Karaganda Medical University; Phase II–IV across internal medicine, cardiovascular, pulmonology, and occupational medicine reflecting the industrial Karaganda region's patient profile; important for sponsors seeking central Kazakhstan patient coverage and access to a mining and heavy industry workforce population with distinct occupational health and respiratory disease patterns. |
| 09 | South Kazakhstan Medical Academy Hospital | Shymkent | Southern Kazakhstan's primary academic hospital, serving a densely populated region with one of the country's youngest demographics; Phase II–III across cardiovascular, oncology, and internal medicine; access to southern Kazakhstan's Uzbek-influenced cultural and genetic patient population, including elevated esophageal cancer incidence from the Central Asian dietary corridor; growing commercial trial portfolio linked to Shymkent's rapid population growth. |
| 10 | West Kazakhstan Marat Ospanov Medical University Hospital | Aktobe | Western Kazakhstan's academic teaching hospital, serving the oil-rich Aktobe region and the broader western steppe population; Phase II–III in cardiovascular disease, internal medicine, and occupational medicine; access to the West Kazakhstan patient population including communities with petroleum industry occupational exposure patterns; important regional site for sponsors seeking all-Kazakhstan geographic enrollment breadth in multi-site trial designs. |
| 11 | Republican Center for Phthisiopulmonology | Almaty | Kazakhstan's national specialist centre for tuberculosis and pulmonary medicine, reflecting the country's historically significant TB burden including multidrug-resistant strains; Phase II–IV in pulmonary TB, MDR-TB, extensively drug-resistant TB (XDR-TB), and COPD; a well-characterised and medically supervised TB patient cohort of direct relevance to sponsors in anti-infective, antimicrobial, and pulmonary drug development pipelines. |
| 12 | Republican Children's Clinical Hospital | Astana | Kazakhstan's national paediatric referral hospital in the capital; Phase II–IV in paediatric oncology, rare genetic diseases, haematology, and metabolic disorders; national catchment covering the full pediatric population of Kazakhstan with referrals from all regional children's hospitals; relevant for sponsors targeting paediatric rare disease indications given Kazakhstan's population size and the relatively low prior paediatric trial participation across Central Asia. |
Kazakhstan's oldest and most prestigious medical institution (founded 1930) and the backbone of the national investigator pipeline; affiliated clinical hospitals serving as the primary academic trial base in Almaty; Phase II–IV across cardiovascular, oncology, neurology, endocrinology, and infectious disease; the primary portal for international sponsors building first Kazakhstani site relationships, with the deepest GCP-trained investigator community in Central Asia.
Kazakhstan's national cancer research institute and the primary oncology trial site in the country; KazNMU affiliate; Phase I–IV across solid tumours and haematologic malignancies; the leading site for esophageal cancer trials given the Central Asian region's world-leading ESCC incidence rates; active participation in CIS oncology research networks and growing international commercial sponsor partnerships.
Kazakhstan's premier surgical and cardiovascular research institute, named after the founding figure of Kazakhstani surgery; Phase II–IV in cardiovascular surgery, interventional cardiology, vascular disease, and hepatobiliary surgery; modern infrastructure and a highly experienced investigator team; one of Central Asia's most capable sites for Phase III cardiovascular outcomes and complex surgical indication trial programs.
A major multispecialty diagnostic and clinical research centre in Almaty; Phase II–IV across internal medicine, cardiology, metabolic disease, and rheumatology; large patient throughput from the greater Almaty metropolitan area; established relationships with international CROs and an active commercial Phase III portfolio particularly in cardiovascular and endocrinological indications.
Kazakhstan's flagship academic hospital in the capital, representing the country's most significant post-independence healthcare infrastructure investment; Astana Medical University affiliate; Phase I–IV across cardiology, oncology, neurology, endocrinology, and general surgery; the anchor site for first-in-EAEU trial programs in Astana and increasingly preferred by international sponsors for its modern infrastructure and capital city regulatory access.
Kazakhstan's most internationally oriented hospital, operated in partnership with Nazarbayev University and designed to Western hospital management standards; Phase II–IV across oncology, cardiovascular, and metabolic disease; English-language clinical environment with a faculty recruited from international academic medical centres; the preferred site for sponsors requiring the closest alignment to Western hospital research infrastructure standards within the EAEU.
The clinical base of Semey Medical University, situated in the city adjacent to the former Soviet Semipalatinsk nuclear test site (the Polygon); Phase II–IV with a uniquely deep research heritage in radiation medicine, thyroid oncology, haematological malignancies, and radiation-related conditions in exposed populations; the world's most experienced academic centre for studying long-term radiation health effects in civilian populations; a specialist research asset with no parallel in the region.
Central Kazakhstan's academic teaching hospital and the clinical base of Karaganda Medical University; Phase II–IV across internal medicine, cardiovascular, pulmonology, and occupational medicine reflecting the industrial Karaganda region's patient profile; important for sponsors seeking central Kazakhstan patient coverage and access to a mining and heavy industry workforce population with distinct occupational health and respiratory disease patterns.
Southern Kazakhstan's primary academic hospital, serving a densely populated region with one of the country's youngest demographics; Phase II–III across cardiovascular, oncology, and internal medicine; access to southern Kazakhstan's Uzbek-influenced cultural and genetic patient population, including elevated esophageal cancer incidence from the Central Asian dietary corridor; growing commercial trial portfolio linked to Shymkent's rapid population growth.
Western Kazakhstan's academic teaching hospital, serving the oil-rich Aktobe region and the broader western steppe population; Phase II–III in cardiovascular disease, internal medicine, and occupational medicine; access to the West Kazakhstan patient population including communities with petroleum industry occupational exposure patterns; important regional site for sponsors seeking all-Kazakhstan geographic enrollment breadth in multi-site trial designs.
Kazakhstan's national specialist centre for tuberculosis and pulmonary medicine, reflecting the country's historically significant TB burden including multidrug-resistant strains; Phase II–IV in pulmonary TB, MDR-TB, extensively drug-resistant TB (XDR-TB), and COPD; a well-characterised and medically supervised TB patient cohort of direct relevance to sponsors in anti-infective, antimicrobial, and pulmonary drug development pipelines.
Kazakhstan's national paediatric referral hospital in the capital; Phase II–IV in paediatric oncology, rare genetic diseases, haematology, and metabolic disorders; national catchment covering the full pediatric population of Kazakhstan with referrals from all regional children's hospitals; relevant for sponsors targeting paediatric rare disease indications given Kazakhstan's population size and the relatively low prior paediatric trial participation across Central Asia.
These are the primary regulatory, academic, and industry bodies shaping Kazakhstan's clinical research ecosystem.
Kazakhstan's primary regulatory authority for clinical trial authorization, GCP oversight, and national pharmaceutical policy; oversees the Committee for Medical and Pharmaceutical Control (CMPC) responsible for the technical review of CTA submissions; operates within the EAEU Common Pharmaceutical Market framework, with regulatory decisions recognized across the five EAEU member states.
The supranational regulatory body governing the EAEU Common Pharmaceutical Market across Kazakhstan, Russia, Belarus, Armenia, and Kyrgyzstan; sets unified GCP, GMP, and clinical trial standards under the EAEU pharmaceutical regulatory framework; a CTA submitted and approved under EEC standards covering Kazakhstan generates data recognized across all five EAEU member states; a combined regulatory market of approximately 183 million people.
Kazakhstan's national health analytics and strategic planning centre under the Ministry of Health; coordinates health technology assessment, clinical guideline development, and national medical standards that inform clinical trial protocol acceptability in Kazakhstan; an important stakeholder for sponsors navigating Kazakhstan's national healthcare priority framework for innovative drug access and trial authorization.
Kazakhstan's oldest, largest, and most prestigious medical university, founded in 1930 and the primary backbone of the national investigator pipeline; affiliated with the country's leading Almaty clinical research sites; drives GCP curriculum modernization, international exchange programs, and research partnerships with Russian, European, and Turkish academic medical centres; the institution of origin for the majority of Kazakhstan's senior research-active physician cohort.
Kazakhstan's most internationally oriented medical faculty, established in partnership with leading Western academic institutions and operating in English; faculty recruited from US, European, and Asian medical universities; drives a new generation of GCP-certified Kazakhstani investigators trained to Western research standards; the academic partner of the University Medical Center in Astana; Kazakhstan's most internationally aligned clinical research site.
A uniquely positioned medical university whose research legacy is defined by four decades of studying radiation health effects in the population exposed to the Soviet-era Semipalatinsk nuclear test site; houses specialist expertise in radiation oncology, thyroid disease, haematological malignancies, and radiation epidemiology with no parallel depth anywhere else in Central Asia; a critical partner for sponsors in radiation medicine, thyroid cancer, and population health research programs.
Central Kazakhstan's established medical university with a strong research tradition in cardiovascular disease, pulmonology, and occupational medicine reflecting the Karaganda industrial region's patient demographics; drives the investigator pipeline for central Kazakhstan's trial sites; growing international research connections through EAEU academic networks and bilateral programs with Russian and European medical faculties.
CIS-specialist CRO with established Kazakhstani site relationships and a strong regional track record; Phase II–IV across cardiovascular, oncology, infectious disease, and metabolic indications; full regulatory submission, contracting, and patient recruitment management under the EAEU pharmaceutical framework; extensive experience with multi-country CIS trial designs combining Kazakhstani, Russian, and Ukrainian sites within a unified regulatory submission.
Global CRO with established CIS regional operations covering Kazakhstan; Phase I–IV trial management across all major therapeutic areas; Ministry of Health and CMPC regulatory submission expertise and EAEU framework navigation; site monitoring, data management, and patient recruitment infrastructure across KazNMU, the Kazakh Oncology Institute, Syzganov Center, and Astana's National Scientific Medical Center.
International CRO with CIS regional coverage managing Phase II–IV oncology, cardiovascular, and EAEU market-access trial programs in Kazakhstan; established investigator relationships across Almaty and Astana's major hospital networks; growing capability in esophageal cancer and EAEU-wide regulatory strategy for sponsors seeking Kazakhstan as a gateway to the broader CIS pharmaceutical market.
Global CRO with CIS operations covering Kazakhstan; Phase II–III trial management and EAEU regulatory strategy; Ministry of Health CTA submission expertise for sponsors entering the Kazakhstani market or adding Kazakhstani sites to existing CIS multi-country programs; cardiovascular, oncology, and metabolic disease therapeutic area depth across the Almaty and Astana hospital networks.
Kazakhstan is one of Central Asia's most important clinical research markets, supported by major hospital networks in Almaty and Astana, EAEU regulatory alignment, and patient access across cardiovascular, oncology, infectious disease, metabolic, and respiratory indications. For sponsors building regional portfolios, Kazakhstan can serve as a practical anchor for Central Asia and broader CIS feasibility planning.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.